Home » Corcept Therapeutics Initiates Third Phase III Trial of Corlux
Corcept Therapeutics Initiates Third Phase III Trial of Corlux
May 6, 2005
Corcept Therapeutics has initiated its third Phase III clinical trial designed to evaluate the safety and efficacy of Corlux for the treatment of the psychotic features of psychotic major depression.
Corlux (mifepristone) has been granted fast-track designation for this indication. Corcept anticipates having initial results from this study available by the end of 2006. Results from the company's two ongoing Phase III trials are expected to be reported during the first half of 2006.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct